← SynDRA
GSK-1838705A
SynDRA canonical compound SYN1953916 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
| Primary target(s) | ALK | IGF1R | INSR | RPS6KA1 |
| Mechanism of action | insulin growth factor receptor inhibitor |
All known targets
Mechanisms of action (all sources)
- insulin growth factor receptor inhibitor
Cross-references
Synonyms
- GSK 1838705A
- GSK1838705A
- GSK1838705
- 2-((2-((1-(2-(Dimethylamino)acetyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide
- GSK 1838705
- 2-(2-(1-(2-(dimethylamino)acetyl)-5-methoxyindolin-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-6-fluoro-N-methylbenzamide
- 2-[[2-[[1-[(Dimethylamino)ethanoyl]-5-(methyloxy)-2,3-dihydro-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide
- 2-[[2-[[1-[2-(dimethylamino)acetyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide
- 2-[[2-[[1-[2-(Dimethylamino)acetyl]-2,3-dihydro-5-methoxy-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide
- 2-{[2-({1-[2-(dimethylamino)acetyl]-5-methoxy-2,3-dihydro-1H-indol-6-yl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-6-fluoro-N-methylbenzamide
- MLS006010967
- CHEMBL464552
- GTPL5683
- SCHEMBL2205605
- SCHEMBL12428872
- BDBM27817
- CHEBI:93768
- DTXSID50648971
- EX-A301
- HMS3656L15
- BCP02847
- MFCD19443644
- NSC766255
- ZINC43202844
- AKOS024458500
- AKOS025149101
- BCP9000736
- CCG-269927
- CS-0695
- NSC-766255
- pyrrolo[2,3-d]pyrimidine deriv., 40
- SB19386
- NCGC00346647-01
- NCGC00346647-09
- NCGC00346647-15
- 2-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide
- 2-[(2-{[1-(N,N-dimethylglycyl)-5-(methyloxy)-2,3-dihydro-1H-indol-6-yl]amino}-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-6-fluoro-N-methylbenzamide
- AC-32802
- AS-16914
Look up GSK-1838705A in the interactive SynDRA portal →